#USA #Milford #Waters #BioResolve #MaxPeak

Waters Introduces BioResolve Protein A Affinity Columns

Waters Corporation has made a noteworthy advancement in the field of bioprocessing with the launch of its BioResolve™ Protein A Affinity Columns equipped with MaxPeak™ Premier Technology. This innovative product aims to revolutionize how antibody titer measurements are conducted, allowing researchers and bioprocess engineers to gain results significantly faster than ever before.

The new columns enable up to 2 days earlier access to antibody titer measurements, thereby facilitating both clone selection and bioprocess monitoring. By employing a novel high-efficiency particle technology, the new BioResolve columns provide a seven-fold increase in sensitivity compared to leading competitors. This technological leap represents a game-changer for the biopharmaceutical industry, where speed and accuracy are crucial.

Dr. Udit Batra, President and CEO of Waters Corporation, expressed his optimism regarding this advancement, stating, “The launch of the BioResolve Protein A Affinity Columns will contribute to getting life-saving therapies to patients more quickly.” He further highlighted that one of the major bottlenecks in developing biotherapeutics, particularly monoclonal antibodies, is the time-consuming process of identifying and optimizing suitable cell lines for antibody production. This new product addresses this challenge effectively with a unique combination of immobilized Protein A surface and MaxPeak hardware, resulting in the most sensitive Protein A column available on the market.

The BioResolve Protein A Affinity Columns are designed for tandem use with size exclusion chromatography (SEC) columns. This integration allows for titer concentrations and aggregate analyses to be performed within a single run on any liquid chromatography (LC) system, simplifying workflows and providing dual insights into antibody quality metrics.

Furthermore, the new columns allow for antibody titers to be detected at drastically lower concentrations, specifically seven-fold lower than the leading competitor, using ultra-high-performance liquid chromatography (U(H)PLC) techniques with low dispersion. This means researchers can obtain quantitative measurements sooner by utilizing standard doubling times of CHO cell lines, ultimately speeding up the development cycle of biopharmaceutical products.

Arnaud Delobel, Director of R&D and Innovation at Quality Assistance, noted, “The new column enhances our ability to support our customers in developing new medications.